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Background. Selective serotonin reuptake inhibitors take several weeks to achieve their full antidepressant effects.
Post-synaptic 5-HT2A receptor activation is thought to be involved in this delayed therapeutic effect. Pipamperone
acts as a highly selective 5-HT2A/D4 antagonist when administered in low doses. The purpose of this study was to
compare citalopram 40 mg once daily plus pipamperone 5 mg twice daily (PipCit) versus citalopram plus placebo
twice daily for magnitude and onset of therapeutic effect.
Method. An 8-week, randomized, double-blind study in patients with major depressive disorder was carried out.
Results. The study population comprised 165 patients (citalopram and placebo, n=82 ; PipCit, n=83) with a mean
baseline Montgomery–Asberg Depression Rating Scale (MADRS) score of 32.6 (S.D.=5.5). In the first 4 weeks, more
citalopram and placebo than PipCit patients discontinued treatment (18% v. 4%, respectively, p=0.003). PipCit
patients had significantly greater improvement in MADRS score at week 1 [observed cases (OC), p=0.021 ; last
observation carried forward (LOCF), p=0.007] and week 4 (LOCF, p=0.025) but not at week 8 compared with
citalopram and placebo patients. Significant differences in MADRS scores favoured PipCit in reduced sleep, reduced
appetite, concentration difficulties and pessimistic thoughts. Mean Clinical Global Impression–Improvement scores
were significantly improved after 1 week of PipCit compared with citalopram and placebo (OC and LOCF, p=0.002).
Conclusions. Although the MADRS score from baseline to 8 weeks did not differ between groups, PipCit provided
superior antidepressant effects and fewer discontinuations compared with citalopram and placebo during the first
4 weeks of treatment, especially in the first week.
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Introduction
Major depressive disorder (MDD) is a common,
serious and disabling mental illness that has a serious
impact on patients, their families and caregivers. It is
associated with a high level of personal disability,
poor quality of life, high morbidity and high risk of
suicide, as well as high direct (healthcare utilization)
and indirect (lost workdays) cost. The World Health
Organization estimates that MDD will be the number
one cause of disability in both the developed and de-
veloping worlds by 2030 (WHO, 2008).
Typically, antidepressant pharmacotherapy is used
for patients with MDD, with selective serotonin
reuptake inhibitors (SSRIs) and selective serotonin–
noradrenaline reuptake inhibitors (SNRIs) considered
first-line treatment options. However, approximately
40% of patients do not respond to initial
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antidepressant treatments (Anderson, 2003), and more
than half (55–73%) do not achieve remission of symp-
toms (Thase et al. 2001 ; Gaynes et al. 2008). In addition,
current treatments have a delayed onset of action, with
antidepressants typically requiring 4–6 weeks to
achieve full therapeutic effect. Other drawbacks are
reduced treatment compliance and early treatment
discontinuation ; 28% of patients discontinue anti-
depressant treatment within the first month (Masand,
2003). The delay in efficacy seen with current therapies
is likely to contribute to poor compliance and early
treatment discontinuation (Machado-Vieira et al. 2008).
Hence, there is a clinical need for therapies with faster
onset of antidepressant effects not only to reduce de-
pressive symptoms quickly, but also to help improve
patient compliance and outcomes (Keller et al. 2002).
There is considerable evidence that depression
is associated with a relative reduction in activity of
serotonergic neurons, the so-called serotonin hypo-
thesis of depression. Multiple malfunctions in the
serotonin system, both presynaptic and postsynaptic,
have been documented in depression and suicide
(Celada et al. 2004 ; Gillespie et al. 2009).
SSRIs deactivate the serotonin transporter, thereby
preventing the presynaptic reuptake of serotonin and
increasing the synaptic concentrations of serotonin.
This results in increased stimulation of all serotonin
receptors, including the postsynaptic 5-HT1A receptor.
The therapeutic mode of action of SSRIs is not fully
understood, but the increased extracellular fluid con-
centrations of serotonin also activate 5-HT2A receptors
by a negative feedback mechanism, which is believed
to reduce 5-HT1A receptor stimulation. This may
partly account for the delayed onset of the therapeutic
effect of SSRIs ; a negative feedback mechanism
operating at presynaptic 5-HT1A autoreceptors in re-
sponse to increased synaptic serotonin concentrations
may also be involved. In this hypothesized feedback
mechanism, activation of the 5-HT1A autoreceptors
dampens firing of serotonergic neurons, thus reducing
the synaptic serotonin concentrations until autorecep-
tor desensitization occurs (Kinney et al. 2000 ; Artigas,
2001 ; Watson & Dawson, 2007 ; Moulin-Sallanon et al.
2009). The key role of 5-HT1A stimulation is supported
by a recent report that polymorphisms of the 5-HT1A
receptor correlate with differential responses to anti-
depressant drugs (Kato et al. 2009). Another mechan-
ism that could explain the lack of optimal response to
SSRIs is their effect on noradrenergic transmission,
because evidence from animal models has shown that
serotonin reuptake inhibition also reduces the firing of
noradrenaline (NE) neurons. This effect is mediated by
increased activation of excitatory 5-HT2A receptors on
inhibitory G-aminobutyric acid (GABA) interneurons
(Blier et al. 2005). Use of a highly selective 5-HT2A
antagonist combined with a SSRI was suggested to
enhance stimulation of postsynaptic 5-HT1A receptors
(Celada et al. 2004; Landen & Thase, 2006), and con-
comitantly prevent dampening of noradrenergic tone
(Blier et al. 2005), thus increasing the efficacy of SSRIs.
However, because blocking of 5-HT2A transmission
is associated with enhancing the availability of dopa-
mine in mesocortical systems, increased dopamine
D4 receptor activation may result in behavioural
deregulation (Svensson & Mathe, 2002). Thus, simul-
taneous blockade of 5-HT2A and D4 receptors has been
postulated as a means of improving the therapeutic
effect of SSRIs.
Pipamperone is a relatively weak neuroleptic drug
approved in some European countries. At its usually
recommended antipsychotic dose (120–360 mg/d), it
has relatively weak neuroleptic activity because it is
only moderately effective as a dopamine D2-receptor
antagonist, even at high doses. At low doses
(5–15 mg/d), pipamperone is a highly selective dopa-
mine D4 and 5-HT2A receptor antagonist (Buntinx et al.
2008 ; Peremans et al. 2008). With these pharmacologic
properties, we hypothesized that pipamperone will
block 5-HT2A activity, leading to increased serotonin
receptor (including 5-HT1A) signal transduction in
postsynaptic neurons, and also block dopamine D4
receptors. As such, pipamperone should increase the
antidepressant effect of SSRIs or SNRIs.
The present study was designed to test this
hypothesis, by comparing the combination of citalo-
pram, a highly selective SSRI with a favourable ad-
verse event profile, plus low doses of pipamperone
versus citalopram and placebo in terms of both the
magnitude and onset of antidepressant effect.
Method
Patient population
Eligible patients were aged 18–65 years, had sponta-
neously reported to their primary-care physician, and
were diagnosed with moderate to severe MDD based
on DSM-IV criteria (APA, 2000) with depressed mood
and loss of interest/anhedonia lasting from 4 to
26 weeks. The diagnosis of MDD was confirmed by
the Mini International Neuropsychiatric Interview,
version 5.0.0. Inclusion criteria also required a Clinical
Global Impression – Severity of Illness (Guy, 1976)
score of o4 (moderately ill), a 17-item Hamilton
Depression Scale (Hamilton, 1960) total score of
o18, and a non-psychotic state. Exclusion criteria
included: significant risk of suicide or scoring o5
on the Montgomery–Asberg Depression Rating Scale
(MADRS; Montgomery & Asberg, 1979) item 10
(suicidal thoughts) ; resistant depression as defined by
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failure to respond to two previous antidepressants
(taken at adequate dosage for o4 weeks during the
current episode) or failure to respond to augmentation
therapy with an atypical antipsychotic drug; and sig-
nificant physical illness, excessive alcohol use, or other
psychiatric illness that could interfere with trial as-
sessments. Patients with epilepsy, history of cardiac
dysrhythmia, or renal or hepatic impairment, women
who were pregnant or breast-feeding, and those who
had recently used antidepressants, benzodiazepines,
or other psychotropic agents or had electroconvulsive
therapy during the current episodewere also excluded.
The study was conducted in central Scotland by
CPS Research using a network of primary care phys-
icians. Trained research nurses visited the sites to assist
in carrying out study assessments to ensure homo-
geneity. The clinical study protocol was approved by
the relevant ethics committees, and written informed
consent was obtained from all patients before en-
rolment in the study.
Study design
This was a phase IIa, randomized, double-blind,
parallel-group study in patients with MDD (Clinical-
trials.gov identifier no. NCT00672659). Patients were
randomly assigned to receive pipamperone 5 mg
twice daily (BID) and citalopram 40 mg once daily
(QD) (PipCit) or citalopram 40 mg QD and placebo
BID (in a ratio of 1 :1) orally for 8 weeks. In both
groups, treatment with citalopram was started at a
dose of 20 mg QD, which was force-titrated up to
40 mg QD after 1 week. Efficacy and safety were as-
sessed at baseline (week 0), at weeks 1, 2, 4, 6 and 8,
and with a telephone follow-up 28 days after the final
clinic visit.
Randomization and blinding
Patients were randomly assigned to treatment groups
using an interactive voice response system provided
by the Robertson Centre for Biostatistics at the
University of Glasgow. This system instructed the site
which treatment pack number had been assigned to
each patient. All study personnel and participants
were blinded to the treatment assignment for the
duration of the study. The use of placebo capsules
identical to pipamperone capsules (apart from the lack
of active ingredient) and identical packaging and
labelling ensured that both the patient and investi-
gator were blinded to the administered treatment.
Objectives
The primary objective of the study was to determine
whether combining pipamperone with citalopram in
patients with MDD augments the therapeutic effect
obtained with citalopram monotherapy. The main
secondary objectives were to determine whether the
addition of pipamperone to citalopram accelerates the
onset of the therapeutic effect and to assess the safety
and tolerability of the combination regimen.
Outcome measures
The primary outcome measure, as defined in the
protocol, was the mean change in MADRS score from
baseline to week 8. Secondary outcome measures
included mean changes in the MADRS scores from
baseline to weeks 1, 2, 4 and 6, and mean changes in
Clinical Global Impression – Improvement (CGI-I)
scale and Beck Depression Inventory (BDI) scores at
weeks 1, 2, 4, 6 and 8. The number of patients re-
sponding, or partially responding (o50%, or o20%
improvement from MADRS baseline score, respec-
tively) were determined at weeks 1, 2, 4, 6 and 8. The
number of patients with a sustained response or a
partial response (o50% oro20% improvement from
baseline score at weeks 2 and 4, respectively), and
sustained remission (MADRS score f10 at weeks 6
and 8) were also determined.
Safety and tolerability were assessed by: the evalu-
ation of treatment-emergent adverse events, treatment-
related adverse events, and discontinuations due to
adverse events ; laboratory tests, including serum
prolactin and electrocardiogram (ECG) ; vital signs ;
and physical examination including body weight.
Sample size
It was estimated that 65 patients per group were re-
quired to detect a significant difference in the primary
outcome variable between PipCit and citalopram at the
5% level with 90% power, assuming a 30% improve-
ment in the performance of the combination over
citalopram and placebo. Assumptions on the perform-
ance of citalopram were based on the performance of
escitalopram in a previous study in patients with a
baselineMADRS score of 28.7 (Wade& Friis Andersen,
2006). To account for loss to follow-up (21%), the target
recruitment number of patients was 165.
Statistical methods
The primary analysis comparing the change in
MADRS score from baseline to week 8 between
treatment groups was analysed using the two-sample
t test with the estimated between-group difference.
For the secondary analyses, the continuous variables
(MADRS, CGI-I and BDI scores) were compared
between treatment groups using the two-sample t test
or a linear regression model, and the categorical
variables (numbers of patients who discontinued,
achieved response, or achieved remission) were
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analysed using a Fisher exact test or a logistic re-
gression model. Mixed-effects models for repeated
measures (MMRM) were used to estimate the differ-
ence between treatment groups over the 8 weeks.
Post-hoc MMRM analyses were also performed over
the first 4 weeks. Treatment group, time point, baseline
score (where applicable), age, sex, duration of current
episode of MDD >12 weeks, and history of two
previous psychiatric conditions were included in the
MMRM model. General covariance structures were
assumed in all models. MADRS item scores were also
analysed using the above methods in post hoc analyses.
Statistical analyses were performed using S-Plus for
Windows, version 7.0 or higher (Tibco, USA). The
intent-to-treat population, which consisted of all
randomized patients, was used to analyse all efficacy
outcome variables, body weight and serum prolactin.
Patients were analysed according to the group
assignment. Analyses were performed on observed
cases (OC) and using the last observation carried for-
ward (LOCF) approach to account for missing data.
Treatment differences were reported with 95% confi-
dence intervals (CIs) and p values. No corrections
were made for multiple analyses. Adverse event data
have been summarized descriptively for the safety
population, which included all randomized patients
who received at least one dose of study medication.
Results
Patient disposition
A total of 172 patients were enrolled in the study
between February and November 2008; 165 patients
were randomized to treatment (citalopram and
placebo, n=82 ; PipCit, n=83). The last patient com-
pleted the study in February 2009. A Consolidated
Standards of Reporting Trials (CONSORT) flow dia-
gram is given in Fig. 1. The proportion of patients
discontinuing the study before endpoint was not
significantly different between the treatment groups
[citalopram and placebo, 21/82 (26%) ; PipCit, 14/83
(17%); p=0.19]. However, in the first 4 weeks of
treatment a higher number of patients discontinued
from the citalopram and placebo treatment group
[15/82 (18%)] than from the PipCit group [3/83 (4%),
p=0.003]. The main reason for discontinuation from
both treatment groups was ‘ loss to follow-up’.
Patient characteristics
At baseline, the treatment groups had generally simi-
lar demographic and clinical characteristics (Table 1).
However, there were more women and patients with
any psychiatric history in the PipCit group than in the
citalopram and placebo group. Most patients were
women and 70% had severe depression (MADRS
score o30). Treatment compliance over the 8-week
period was >95% in both groups, and there were no
significant between-group differences in the use of any
class of concomitant medication.
Efficacy
In the primary analysis, there was no evidence that the
change in MADRS score from baseline to 8 weeks dif-
fered between the groups (OC two-sample t test : esti-
mated difference, 0.1, 95% CI x3.0 to 3.3, p=0.943).
Enrolled (n=172)
Randomized (n=165)
Allocated to citalopram (n=82) - ITT
Received citalopram (n=80) - safety
Did not receive citalopram (n=2)
Allocated to PipCit (n=83) - ITT
Received PipCit (n=83) - safety
Completed study (n=61) Completed  study (n=69)
Discontinued (n=21)
Adverse event (n=4)
Lost to follow-up (n=8)
Unwilling to continue (n=5)
Noncompliance (n=1)
Investigator advice (n=2)
Other (n=1)
Discontinued (n=14)
Adverse event (n=2)
Lost to follow-up (n=6)
Unwilling to continue (n=2)
Noncompliance (n=2)
Lack of efficacy (n=1)
Other (n=1)
Included in primary analysis (n=62)
Excluded from primary analysis (n=20)
Reason: No 8-week data (n=20)
Included in primary analysis (n=69)
Excluded from primary analysis (n=14)
Reason: No 8-week data (n=14)
Excluded (n=7)
Failed to meet eligibility criteria (n=7)
Fig. 1. Patient disposition. ITT, Intent to treat ; PipCit, citalopram 40 mg once daily plus pipamperone 5 mg twice daily.
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However, as shown in Fig. 2, there was evidence of a
difference between treatment groups at other time
points. In both the OC and LOCF, the PipCit group
had a significantly greater reduction in MADRS score
compared with the citalopram+placebo group at 1
week (OC two-sample t test estimated difference on
change from baseline x2.14, 95% CI x3.95 to x0.33,
p=0.021 ; LOCF estimated difference x2.43, 95% CI
x4.18 tox0.68, p=0.007). At week 2 there was a non-
significant improvement using LOCF (p=0.089), but
there was again significant improvement in MADRS
score from baseline at week 4 in the LOCF (estimated
difference, x2.95, 95% CI x5.53 to x0.37, p=0.025).
Similar results were obtained when the data were
analysed using a linear regression model.
The MADRS total scores and item scores that
showed any significant treatment effect differences
averaged over 4 and/or 8 weeks, estimated using
an MMRM for OC and LOCF, are summarized in
Table 2. A significant benefit in favour of PipCit was
demonstrated over 4 weeks (LOCF, p=0.004). Over
8 weeks, a numerical advantage that failed to reach
significance (LOCF, p=0.063) was observed in favour
of PipCit. Among OCs, no significant differences were
observed in total MADRS scores, but there were
significant improvements in the PipCit group com-
pared with the citalopram and placebo group in
reducing sleep-related problems over 4 and 8 weeks
and appetite-related problems over 4 weeks. Using an
LOCF analysis, the PipCit group was superior to the
citalopram+placebo group in improving depressive
symptoms related to sleep (4 and 8 weeks), appetite
(4 and 8 weeks), concentration (4 weeks) and pessi-
mistic thoughts (8 weeks).
Response by MADRS criteria using LOCF was sig-
nificantly more likely in the PipCit group than in the
citalopram and placebo group over the first 4 weeks
(MMRM, odds ratio 2.18, 95% CI 1.18–4.02, p=0.013),
but not over 8 weeks (MMRM, odds ratio 1.62, 95% CI
0.96–2.73, p=0.071). There was no evidence of any
between-group differences in partial MADRS re-
sponse, sustained early partial response, remission or
sustained remission rates during the study. Sustained
early response was achieved by 21% (17/80) of PipCit
patients compared with 9% (6/67) of citalopram and
placebo patients (OC) (Fisher exact test, p=0.067) ; the
difference was significant using a logistic regression
model (odds ratio 2.9, 95% CI 1.0–8.1, p=0.046). Using
the LOCF approach, the treatment differences ap-
proached significance with both analyses.
The PipCit group had a significantly greater
improvement on the CGI-I than the citalopram and
placebo group at week 1 (OC and LOCF, two-sample
t test : estimated difference x0.39, 95% CI x0.64 to
x0.14, p=0.002), but there were no significant differ-
ences in CGI-I between the groups at any other time
point. There was no evidence of any significant
between-group differences on the BDI.
A post hoc analysis comparing the changes in
total MADRS score from baseline in patients who
discontinued in the first 2 weeks with patients who
continued treatment for the full 8 weeks demonstrated
that the early drop-outs had significantly less im-
provement in symptoms at week 1 than those con-
tinuing treatment (p=0.014, Wilcoxon).
Safety and tolerability
Treatment-emergent adverse events with an incidence
of o5% for either treatment group are shown in
Table 3. The adverse event profile of both treatment
groups was similar with no significant between-
group differences. Both treatments were generally
well tolerated.
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Fig. 2. Change in depressive symptoms according to the
Montgomery–Asberg Depression Rating Scale (MADRS)
score from baseline to each scheduled visit in the intent-
to-treat population : (a) observed cases analyisis and
(b) last observation carried forward (LOCF) analysis.
–2–, Citalopram; - -&- -, citalopram 40 mg once daily plus
pipamperone 5 mg twice daily (PipCit). Values are means,
with standard deviations represented by vertical bars.
Mean value was significantly different from that of the
citalopram group: * p<0.05, ** p<0.01.
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The mean increase in serum prolactin from baseline
to week 8 was significantly greater in the PipCit group
than in the citalopram and placebo group (3.75 v. 0.74
ng/ml, estimated difference 3.01, 95% CI 1.01–5.01,
p=0.003). However, there were no cases of hyperpro-
lactinaemia in either treatment group at week 8. Other
laboratory results were unremarkable.
As shown in Fig. 3, we found that there were sig-
nificant between-group differences in body weight
during the 8 weeks. The PipCit group had significantly
increased weight compared with the citalopram+
placebo group at 2 weeks (p<0.05), 4 weeks (p<0.001),
6 weeks and 8 weeks (p<0.01), the difference also
being significant over the 8 weeks (overall MMRM,
p=0.001). However, the changes were not significant
within the treatment groups. There were no clinically
relevant differences between the treatment groups
regarding ECG or physical examinations.
Discussion
This exploratory study was the first randomized
double-blind evaluation of low-dose pipamperone as
an adjunct to citalopram. The main aim of the study
Table 2. Treatment effect differencea over 4 and 8 weeks between PipCit and citalopram+placebo for MADRS total and item scores
Treatment effect difference (95% CI) : PipCit – citalopram
Over 4 weeks p Over 8 weeks p
OC
MADRS total score x1.59 (–3.30 to 0.12) 0.068 x0.52 (–2.31 to 1.27) 0.567
MADRS item scoresb
Reduced sleep x0.58 (–0.93 tox0.22) 0.002 x0.43 (–0.78 tox0.08) 0.015
Reduced appetite x0.33 (–0.65 tox0.01) 0.041 x0.20 (–0.50 to 0.09) 0.173
Concentration difficulties x0.18 (–0.40 to 0.04) 0.114 x0.07 (–0.31 to 0.16) 0.527
Pessimistic thoughts x0.16 (–0.40 to 0.09) 0.208 x0.16 (–0.38 to 0.06) 0.152
LOCF
MADRS total score x2.62 (–4.40 tox0.85) 0.004 x1.86 (–3.82 to 0.10) 0.063
MADRS item scoresb
Reduced sleep x0.68 (–1.03 tox0.33) <0.001 x0.58 (–0.93 tox0.23) 0.001
Reduced appetite x0.39 (–0.70 tox0.07) 0.017 x0.30 (–0.60 to 0.00) 0.048
Concentration difficulties x0.28 (–0.50 tox0.06) 0.013 x0.23 (–0.47 to 0.00) 0.054
Pessimistic thoughts x0.24 (–0.48 to 0.00) 0.051 x0.28 (–0.51 tox0.05) 0.019
PipCit, Citalopram 40 mg once daily plus pipamperone 5 mg twice daily ; MADRS, Montgomery–Asberg Depression Rating
Scale ; CI, confidence interval ; OC, observed cases ; LOCF, last observation carried forward.
a Estimated using a mixed-effects model for repeated measures in the intent-to-treat population.
bMADRS item scores were analysed post hoc.
Table 1. Demographic and clinical characteristics of the study population at baseline
Citalopram
(n=82)
PipCit
(n=83)
Total
(n=165)
Women, n (%) 63 (77) 70 (84) 133 (81)
White, n (%) 82 (100) 82 (99) 164 (99)
Mean age, years (S.D.) 39.7 (11.8) 40.1 (11.4) 39.9 (11.6)
Mean body weight, kg (S.D.) 79.9 (23.7) 80.0 (22.2) 79.9 (22.9)
Duration of current MDD episode, days (S.D.) 99.5 (43.1) 94.8 (37.7) 97.2 (40.4)
Duration of current MDD episode>12 weeks, n (%) 46 (56) 43 (52) 89 (54)
Mean MADRS score (S.D.) 32.4 (5.9) 32.7 (5.1) 32.6 (5.5)
MADRS scoreo30, severe depression, n (%) 58 (71) 57 (69) 115 (70)
Mean CGI-S score (S.D.) 4.8 (0.7) 4.7 (0.7) 4.8 (0.7)
Other previous psychiatric history, n (%) 53 (65) 65 (78) 118 (72)
PipCit, Citalopram 40 mg once daily plus pipamperone 5 mg twice daily ; S.D., standard deviation ; MDD, major depressive
disorder ; MADRS, Montgomery–Asberg Depression Rating Scale ; CGI-S, Clinical Global Impression – Severity of Illness.
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was to assess whether low-dose pipamperone en-
hances the magnitude or onset of the therapeutic effect
of citalopram in patients with moderate to severe
MDD.
PipCit showed a significant advantage over citalo-
pram and placebo in magnitude of antidepressant
effect in the early weeks of the study (weeks 1 and 4)
but statistical significance was lost at weeks 6 and 8.
Improved sleep and appetite were the main symptoms
that improved with PipCit compared with citalopram
and placebo.
Study completion rates were within the expected
ranges for depression studies : 74% with citalopram
and placebo and 83% with PipCit. In the first 4 weeks,
18% of citalopram and placebo patients had with-
drawn, compared with only 4% of PipCit patients.
Thereafter, more PipCit patients withdrew, partially
restoring the balance. The exact reasons for the differ-
ent withdrawal patterns are unclear. The lower rate of
discontinuation in the PipCit group during the first
4 weeks may be clinically important. Higher drop-out
rates in short-term studies are usually associated with
higher adverse event rates (Demyttenaere et al. 2001).
In this study, adverse event profiles were similar,
suggesting that the early lower rate of discontinuation
in the PipCit group may reflect a more rapid anti-
depressant action, with patients staying in the study
because they felt some benefit from treatment.
Delayed onset of action with antidepressants
has also been reported as a cause of poor treatment
adherence (Keller et al. 2002). A post-hoc analysis
demonstrated that patients who had dropped out in
the first 2 weeks of the study also had significantly less
improvement in symptoms at week 1 than did those
patients who continued with treatment, a finding that
supports this hypothesis.
The main limitation of the study is the dispro-
portionate rate of discontinuation between the treat-
ment groups in the first 4 weeks of treatment. The
exact reasons for discontinuation are unknown in the
majority of cases (loss to follow-up, 14 out of 35;
inability to continue, seven out of 35), and it would
be important for future studies to document this
more thoroughly. Bias may result when the reasons for
discontinuation are unknown, especially if there is a
between-group difference in drop-out rates, as was
observed in this study.
The LOCF approach was originally specified as a
means of partially offsetting the uncertainty associated
with discontinuations. However, because more citalo-
pram and placebo patients withdrew in the first
Table 3. Treatment-emergent AEs in the safety population
Citalopram+
placebo
patients
(n=80), n (%)
PipCit
patients
(n=83),
n (%)
Any AEs 67 (84) 77 (93)
Severe AEs 1 (1) 1 (1)
Treatment-related AEs 44 (55) 51 (61)
Possibly treatment-related 25 (31) 31 (37)
Probably treatment-related 18 (23) 19 (23)
Definitely treatment-related 1 (1) 1 (1)
Serious AEs 1 (1) 0 (0)
Serious treatment-related AEs 0 (0) 0 (0)
Discontinuations due to AEs 4 (5) 1 (1)
AEs reported ino5% of patients
in either treatment group
Headache 19 (24) 21 (25)
Nausea 26 (33) 19 (23)
Dry mouth 6 (8) 12 (14)
Diarrhoea 13 (16) 10 (12)
Fatigue 8 (10) 9 (11)
Dizziness 6 (8) 8 (10)
Hyperhidrosis 9 (11) 7 (8)
Night sweats 2 (3) 7 (8)
Upper respiratory tract infection 9 (11) 6 (7)
Tremor 4 (5) 6 (7)
Vomiting 4 (5) 5 (6)
Nasopharyngitis 7 (9) 5 (6)
Cough 3 (4) 5 (6)
Lower respiratory tract infection 3 (4) 4 (5)
Lethargy 4 (5) 2 (2)
Rash 4 (5) 2 (2)
AE, Adverse event ; PipCit, citalopram 40 mg once daily
plus pipamperone 5 mg twice daily.
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Fig. 3. Body weight over time (mixed-effects model for
repeated measures estimates), intent-to-treat population,
observed cases. –2–, Citalopram; - -&- -, citalopram 40 mg
once daily plus pipamperone 5 mg twice daily (PipCit).
Values are means, with standard deviations represented by
vertical bars. Mean value was significantly different from that
of the citalopram group : * p<0.05, ** p<0.01, *** p<0.001.
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4 weeks, the LOCF analysis tended to accentuate
early differences between treatment groups in favour
of PipCit. However, the majority of the drop-outs at
week 2 had not improved significantly in the first
week, raising the possibility that significant later
improvement in these patients would be limited
(Stassen et al. 1998). Hence, the LOCF approach may
yield clinically meaningful results. These conclusions
are further supported – albeit with limited statistical
significance – by an MMRM analysis that demon-
strated a similar pattern of early benefit with PipCit.
In this study, pipamperone was used at a dosage
four to 36 times lower than that used in routine clinical
practice. Hence, problems with specific adverse events
associated with typical antipsychotic agents were
neither expected nor observed; for example, there
were no reports of extrapyramidal symptoms. PipCit
was generally well tolerated. Body weight initially in-
creased in the PipCit group compared with citalopram
and placebo but then appeared to stabilize. This could
have been caused by improved appetite ; no PipCit
patient reported increased weight as an adverse event.
There was sufficient evidence in this study to sug-
gest that pipamperone has some additional beneficial
effect when used in combination with citalopram at
apparently no detriment to safety. This is of particular
interest because the augmentation with atypical anti-
psychotics (e.g., risperidone, olanzapine, quetiapine)
in patients that fail or only partially respond to an
adequate antidepressant medication leads to more
rapid response and a higher remission rate (Keitner
et al. 2009), but their association with weight gain and
the metabolic syndrome is problematic. Low doses of
pipamperone apparently provide similar therapeutic
advantage without the metabolic adverse events. The
advantages of the observed earlier response are likely
to include improved treatment compliance, which
should further benefit patients’ outcomes.
Further studies with larger patient numbers and
close monitoring of patients’ precise reasons for dis-
continuation are warranted to confirm the impact on
early resolution of depressive symptoms of pipam-
perone in combination with citalopram and to see
whether the improvements observed in this study are
sustained over the long term.
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